Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 8101 to 8140 of 8140 results

  1. Trastuzumab deruxtecan for treating HER2-low metastatic or unresectable breast cancer after chemotherapy [ID3935]

    In development [GID-TA10813] Expected publication date: TBC

    Technology appraisal guidance
    In development

  2. Trifluridine–tipiracil with bevacizumab for treating metastatic colorectal cancer after 2 systemic treatments [ID6298]

    In development [GID-TA11390] Expected publication date: 24 July 2024

    Technology appraisal guidance
    In development

  3. Dupilumab for treating moderate to severe chronic obstructive pulmonary disease ID6235

    In development [GID-TA11246] Expected publication date: TBC

    Technology appraisal guidance
    In development

  4. Mirikizumab for treating moderately to severely active Crohn's disease ID6244

    In development [GID-TA11267] Expected publication date: TBC

    Technology appraisal guidance
    In development

  5. Novel home-testing devices for diagnosing obstructive sleep apnoea/hypopnoea syndrome: diagnostics consultation

    We are listening to your views on this Diagnostics guidance. Comments close 5 June 2024.

    Diagnostics guidance
    In consultation

  6. Belzutifan for previously treated advanced renal cell carcinoma [ID6154]

    In development [GID-TA11086] Expected publication date: TBC

    Technology appraisal guidance
    In development

  7. Harmful gambling: identification, assessment and management

    In development [GID-NG10210] Expected publication date: 16 July 2024

    NICE guideline
    In development

  8. Older people

    All NICE products on older people. Includes any guidance, advice and quality standards.

    Topic page

  9. Pembrolizumab with trastuzumab and chemotherapy for untreated HER2-positive advanced gastric or gastro-oesophageal junction cancer [ID3742]

    In development [GID-TA10615] Expected publication date: TBC

    Technology appraisal guidance
    In development

  10. Digital supported self-management technologies for adults with chronic obstructive pulmonary disease: early value assessment

    In development [GID-HTE10030] Expected publication date: 15 August 2024

    Health technology evaluations
    In development

  11. Semaglutide for preventing major cardiovascular events in people with cardiovascular disease and living with overweight or obesity ID6441

    Awaiting development [GID-TA11544] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  12. Marstacimab for treating severe haemophilia A or severe haemophilia B in people 12 years and over [ID6342]

    In development [GID-TA11397] Expected publication date: TBC

    Technology appraisal guidance
    In development

  13. Nivolumab with ipilimumab for untreated unresectable stage 3 non-small-cell lung cancer [ID6248]

    In development [GID-TA11253] Expected publication date: TBC

    Technology appraisal guidance
    In development

  14. Pembrolizumab with stereotactic body radiotherapy for treating unresected stage 1 or 2 non-small-cell lung cancer [ID6149]

    Awaiting development [GID-TA11093] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  15. Mirvetuximab soravtansine for treating folate receptor alpha-positive platinum-resistant advanced epithelial ovarian, fallopian tube or primary peritoneal cancer ID6442

    Awaiting development [GID-TA11424] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  16. Autologous anti-CD19-transduced CD3+ cells for treating relapsed or refractory mantle cell lymphoma [ID6325]

    In development [GID-TA11545] Expected publication date: 10 September 2025

    Technology appraisal guidance
    In development

  17. Topical rapamycin for treating facial angiofibromas associated with tuberous sclerosis complex in people 6 years and over [ID6391]

    In development [GID-TA11455] Expected publication date: TBC

    Technology appraisal guidance
    In development

  18. Adalimumab for treating early Dupuytren's contracture TS ID 11870

    Awaiting development [GID-TA11363] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  19. Evinacumab for treating homozygous familial hypercholesterolaemia in people aged 12 years and over [ID2704]

    In development [GID-TA10655] Expected publication date: 11 September 2024

    Technology appraisal guidance
    In development

  20. Efanesoctocog alfa for treating and preventing bleeding episodes in haemophilia A [ID6170]: draft guidance

    We are listening to your views on this Technology appraisal guidance. Comments close 10 June 2024.

    Technology appraisal guidance
    In consultation

  21. Toripalimab with chemotherapy for treating advanced oesophageal squamous cell cancer without previous systemic chemotherapy [ID6414]

    Awaiting development [GID-TA11346] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  22. Avacincaptad pegol for treating geographic atrophy caused by age-related macular degeneration [ID6401]

    Awaiting development [GID-TA11511] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  23. Osimertinib with pemetrexed and platinum-based chemotherapy for untreated EGFR mutation-positive advanced non-small-cell lung cancer [ID6328]

    In development [GID-TA11408] Expected publication date: TBC

    Technology appraisal guidance
    In development

  24. Efgartigimod for treating generalised myasthenia gravis [ID4003]

    In development [GID-TA10986] Expected publication date: TBC

    Technology appraisal guidance
    In development

  25. Benralizumab with corticosteroids for treating relapsing or refractory eosinophilic granulomatosis with polyangiitis [ID6266]

    Awaiting development [GID-TA11248] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  26. Pembrolizumab with chemotherapy for neoadjuvant and adjuvant treatment of cisplatin-eligible muscle-invasive bladder cancer [ID6129]

    Awaiting development [GID-TA11137] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  27. Pembrolizumab with chemotherapy for neoadjuvant and adjuvant treatment of cisplatin-eligible muscle-invasive bladder cancer [ID6219]

    Awaiting development [GID-TA11543] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  28. Idebenone for treating visual impairment in Leber's hereditary optic neuropathy in people 12 years and over [ID547]

    In development [GID-TA11288] Expected publication date: TBC

    Technology appraisal guidance
    In development

  29. Asthma: diagnosis, monitoring and chronic asthma management

    In development [GID-NG10186] Expected publication date: 30 October 2024

    NICE guideline
    In development

  30. Trastuzumab deruxtecan for treating HER2-positive unresectable or metastatic breast cancer after 1 or more anti-HER2 treatments [ID6309]

    In development [GID-TA11546] Expected publication date: 10 September 2025

    Technology appraisal guidance
    In development

  31. Efanesoctocog alfa for treating and preventing bleeding episodes in haemophilia A [ID6170]

    In development [GID-TA11106] Expected publication date: TBC

    Technology appraisal guidance
    In development

  32. Iptacopan for treating paroxysmal nocturnal haemoglobinuria [ID6176]

    In development [GID-TA11132] Expected publication date: 26 June 2024

    Technology appraisal guidance
    In development

  33. Dapagliflozin for treating chronic kidney disease [ID6411]

      Status ...

    Technology appraisal guidance
    Topic selection

  34. Olaparib with cediranib for treating platinum-resistant recurrent ovarian cancer after 1 or 2 therapies [ID6129]

    In development [GID-TA11033] Expected publication date: TBC

    Technology appraisal guidance
    In development

  35. Lisocabtagene maraleucel for treating relapsed or refractory diffuse large B-cell lymphoma, high grade B-cell lymphoma, primary mediastinal large B-cell lymphoma or follicular lymphoma grade 3B after first-line chemotherapy [ID3887]

    In development [GID-TA10778] Expected publication date: 11 December 2024

    Technology appraisal guidance
    In development

  36. Ruxolitinib for treating moderate to severe chronic graft-versus-host disease after an allogeneic stem cell transplant in people 28 days to 17 years [ID6427]

    In development [GID-TA11523] Expected publication date: TBC

    Technology appraisal guidance
    In development

  37. Type 2 diabetes in adults: management (medicines update)

    In development [GID-NG10336] Expected publication date: 19 June 2025

    NICE guideline
    In development

  38. Lutetium oxodotreotide with octreotide for newly diagnosed unresectable or metastatic gastroenteropancreatic neuroendocrine tumours [ID6315]

    Awaiting development [GID-TA11366] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  39. Surgical correction of hallux valgus using minimal access techniques

    In development [GID-IPG10339] Expected publication date: 20 June 2024

    Interventional procedures guidance
    In development

  40. Atezolizumab for untreated advanced or recurrent non-small cell lung cancer when platinum-doublet chemotherapy is unsuitable [ID6218]

    In development [GID-TA11139] Expected publication date: TBC

    Technology appraisal guidance
    In development